Cardiac Output
Conditions
Brief summary
To demonstrate that the Impella® Hemodynamic Platform (the Study Device) is safe, and measurements obtained are as good as currently used methods. These measurements include how much pressure the heart is generating and how much blood your heart is pumping during the PCI.
Interventions
DEVICEImpella CP with Smart Assist (Circulatory Support System)
Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
Sponsors
Abiomed Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Subject presents for elective PCI 3. Subject or the subject's LAR has signed the informed consent 4. Subject indicated for Impella® support
Exclusion criteria
1. Any contraindication or inability to place an Impella® including tortuous vascular anatomy, femoral bruits or absent pedal pulses 2. Cardiogenic shock defined as systemic hypotension (SBP\<90mmHg or the need for inotropes/vasopressors to maintain an SBP \>90mmHg) plus one of the following: 1. Any requirement for inotropes/vasopressors prior to arrival at the catherization lab 2. Clinical evidence of end organ hypoperfusion 3. Use of IABP or any other circulatory support device 3. Suspected systemic active infection 4. Suspected or known pregnancy 5. Known contraindication to heparin, pork, pork products, or contrast media 6. Subject has other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent and/or to comply with study procedures 7. Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device which has not reached its primary end point. 8. Subject belongs to a vulnerable population \[Vulnerable subject populations are defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees, and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The ability to calculate and display cardiac output (CO). | Through study completion, approximately 2 days | Defined as the number of times a CO calibration sequence is successfully completed and the CO is displayed divided by the number of times the pinging sequence is attempted. The endpoint is a rate and therefore has no units of measure. It is the number of times CO was successfully completed, and CO is displayed divided by the number of times the pinging sequence was attempted |
Countries
United States
Outcome results
None listed